Financhill
Buy
66

DNTH Quote, Financials, Valuation and Earnings

Last price:
$41.86
Seasonality move :
61.33%
Day range:
$41.46 - $43.40
52-week range:
$13.37 - $45.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
490.74x
P/B ratio:
3.28x
Volume:
319.2K
Avg. volume:
794.4K
1-year change:
81.87%
Market cap:
$1.8B
Revenue:
$6.2M
EPS (TTM):
-$3.49

Earnings Data

Next earnings date for DNTH
Mar 10
2026
Most recent earnings per share
-$0.97
Missed by $0.07
(Nov 5/2025)
Consensus Estimate
-$0.90
(Nov 5/2025)

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

DNTH Quarterly Earnings History

Date Quarter Revenue Forecast Actual Revenue Reported EPS Consensus EPS Beat/Miss
03/10/2026 Q4 $398.1K -- -- -$1.04 --
11/05/2025 Q3 $523.6K $396K -$0.97 -$0.90 -$0.07
08/08/2025 Q2 $864.7K $193K -$0.88 -$0.87 -$0.02
05/08/2025 Q1 $806.9K $1.2M -$0.82 -$0.71 -$0.11
03/11/2025 Q4 $859.7K $1.3M -$0.81 -$0.76 -$0.05
11/07/2024 Q3 $576.4K $2.2M -$0.74 -- --
08/08/2024 Q2 $322.8K $1.9M -$0.51 -- --
05/09/2024 Q1 $371.4K $874K -$0.54 -- --
03/21/2024 Q4 $438.8K $457K -$0.71 -- --
11/09/2023 Q3 $250K $924K -$3.78 -- --
06/30/2023 Q2 -- $969K -$12.73 -- --
03/31/2023 Q1 -- $476K -$129.67 -- --
12/31/2022 Q4 -- $1.2M -$11.57 -- --
09/30/2022 Q3 -- $1.2M -$142.45 -- --
06/30/2022 Q2 -- -- -$4.70 -- --
03/31/2022 Q1 -- -- -$6.25 -- --
12/31/2021 Q4 -- -- -$5.25 -- --
09/30/2021 Q3 -- -- -$4.76 -- --
06/30/2021 Q2 -- -- -$5.04 -- --
03/31/2021 Q1 -- -- -$5.76 -- --
12/31/2020 Q4 -- -- -$5.99 -- --
09/30/2020 Q3 -- -- -$5.86 -- --
06/30/2020 Q2 -- -- -$7.71 -- --
03/31/2020 Q1 -- -- -$8.13 -- --
12/31/2019 Q4 -- -- -$9.52 -- --
09/30/2019 Q3 -- -- -$8.65 -- --
06/30/2019 Q2 -- -- -$7.73 -- --
03/31/2019 Q1 -- -- -$7.10 -- --
12/31/2018 Q4 -- -- -$8.04 -- --
09/30/2018 Q3 -- -- -$7.77 -- --
06/30/2018 Q2 -- -- -$50.09 -- --
03/31/2018 Q1 -- -- -$5.05 -- --
09/30/2017 Q3 -- -- -$3.13 -- --
06/30/2017 Q2 -- -- -$6.96 -- --
03/31/2017 Q1 -- -- -$2.34 -- --

Dianthus Therapeutics, Inc. Earnings Questions

  • How Much did Dianthus Therapeutics, Inc. Generate in Revenue Last Quarter?

    Dianthus Therapeutics, Inc. reported $396K worth of top line sales in its most recent quarter.

  • Did Dianthus Therapeutics, Inc. Beat Earnings Last Quarter?

    Dianthus Therapeutics, Inc. announced earnings per share of -$0.97 which represents a miss of analyst forecast a -$0.90 per share.

  • Is Dianthus Therapeutics, Inc. Profitable?

    Dianthus Therapeutics, Inc. reported $297K that represents $0.01 per share over the last quarter.

  • What is the Analyst Consensus for Dianthus Therapeutics, Inc. EPS Next Year?

    Dianthus Therapeutics, Inc.'s earnings are forecast to decrease from -$2.55 per share to -$2.27 per share next year representing a decrease of -38.79%.

  • When is Dianthus Therapeutics, Inc.'s Earnings Date?

    Dianthus Therapeutics, Inc.'s next earnings date is March 10, 2026.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is DocuSign Stock Undervalued?
Is DocuSign Stock Undervalued?

Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…

Is SentinelOne Stock Undervalued?
Is SentinelOne Stock Undervalued?

Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…

Is Broadcom Stock on Sale?
Is Broadcom Stock on Sale?

Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Buy
72
GLTO alert for Dec 27

Galecto, Inc. [GLTO] is up 16.92% over the past day.

Sell
20
SMX alert for Dec 27

SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.

Sell
11
CDNAF alert for Dec 27

Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock